Clinical trials: P53 Mutation
Acute Myeloid Leukemia, P53 Mutation
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations
This is a prospective,uncontrolled and multi-institution trial.The aim is to identify if using decitabine,cytarabine and ATO as the therapy of acute myeloid leukemia(AML) with p53 mutations has better relapse free survival and…
- Trial name
- NCT03381781
- Testing
- Decitabine, Arsenic Trioxide, Cytarabine
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Li Junmin
Pancreatic Cancer
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
To investigate the safety, tolerability, efficacy and pharmacokinetics of TCR-T cells in the treatment of advanced pancreatic cancer
- Trial name
- GB3010-02 (NCT06054984)
- Testing
- TCR-T Cells Injection（GB3010 Cells Injection）
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Ruijin Hospital
Medulloblastoma
Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant Medulloblastoma
This prospective, open-label, single-arm, multicenter study will evaluate the efficacy and safety of arsenic trioxide (ATO) combined with chemotherapy in pediatric patients with relapsed or refractory SHH-activated…
- Trial name
- NCT07856069
- Testing
- Arsenic Trioxide (ATO), ETOPOSIDE - Study, Cisplatin
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Tumors, Ovarian Cancer
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
Primary Objectives are to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of ZN-c3 and ZN-c3 and bevacizumab or ZN-c3 and bevacizumab plus pembrolizumab in metastatic CCNE1 amplified and TP53 mutant…
- Conditions
- Tumors, Ovarian Cancer, Breast Cancer, Lung Cancer
- Trial name
- NCT05431582
- Testing
- ZN-c3, Bevacizumab, Pembrolizumab
- Sponsor
- M.D. Anderson Cancer Center
Li-Fraumeni Syndrome, Li-Fraumeni-Like Syndrome
Li-Fraumeni Syndrome/TP53 Biobank
Li-Fraumeni Syndrome (LFS) and Li-Fraumeni-like (LFL) Syndrome are cancer predisposition syndromes due to germline aberrations in the TP53 gene.
- Trial name
- NCT04367246
- Testing
- No Intervention
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Epithelial Ovarian Cancer
Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer
The purpose of this study is to determine if patients with p53 mutated epithelial ovarian cancer that have been treated with first line treatment (paclitaxel - carboplatin combination therapy) and that have shown early relapse…
- Trial name
- M10MKO (NCT01164995)
- Testing
- MK-1775 and carboplatin
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- The Netherlands Cancer Institute
Pancreatic Cancer
Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis
Pancreatic cancers represent a challenge for the multidisciplinal team. A patient-tailored treatment plan requires an accurate preoperative staging.
- Trial name
- NCT03524677
- Testing
- Liquid Biopsy
- Where
- 3 sites in Ireland, Italy
- Volunteers
- 50 people
- Sponsor
- University of Roma La Sapienza
Advanced Solid Tumor, Unresectable Solid Tumor
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma
- Trial name
- GUARDIAN-101 (NCT06778863)
- Testing
- CLSP-1025
- Where
- 21 sites in United States
- Volunteers
- 90 people
- Sponsor
- Clasp Therapeutics, Inc.
Advanced Solid Tumors
A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation
This study is to evaluate the safety, tolerability, PK, and preliminary efficacy of NTS071 in adults with TP53 Y220C-mutated solid tumors.
- Trial name
- NTS071 (NCT07060989)
- Testing
- NTS071
- Where
- 10 sites in United States, China
- Volunteers
- 220 people
- Sponsor
- Nutshell Therapeutics (Shanghai) Co., LTD.
Locally Advanced Breast Cancer, Metastatic Breast Carcinoma
The p53 Breast Cancer Trial
This is a multicenter, open labeled, phase 2 clinical trial, where patients are stratified to one of two treatment groups based on upfront TP53 mutation status; i.e. TP53 mutated vs.
- Trial name
- p53b (NCT02965950)
- Testing
- Cyclophosphamide
- Where
- 5 sites in Norway
- Volunteers
- 190 people
- Sponsor
- Haukeland University Hospital
Mitochondrial Disorders, Li-Fraumeni Syndrome
Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome
This study will examine metabolic and biological factors in people with Li-Fraumeni syndrome, a rare hereditary disorder that greatly increases a person's susceptibility to cancer.
- Conditions
- Mitochondrial Disorders, Li-Fraumeni Syndrome, Carriers of p53 Mutation
- Trial name
- NCT00406445
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Recurrent Ovarian Cancer, Recurrent Uterine Cancer
Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer
This is a phase 1 study to evaluate investigational drug RP-6306 in combination with carboplatin and paclitaxel in patients with TP53 mutated ovarian or uterine cancer.
- Conditions
- Recurrent Ovarian Cancer, Recurrent Uterine Cancer, Metastatic Cancer, Advanced Cancer
- Trial name
- GyneRep (NCT06107868)
- Testing
- RP-6306, Carboplatin, Paclitaxel
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- University Health Network, Toronto
Chronic Lymphocytic Leukemia
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in…
- Trial name
- AMPLIFY (NCT03836261)
- Testing
- Acalabrutinib, Venetoclax, Chemoimmunotherapy
- Where
- 169 sites in United States, Argentina and 25 more
- Volunteers
- 984 people
- Sponsor
- Acerta Pharma BV
TP53, Myeloid Tumors
Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT
Recent studies have demonstrated that allogeneic hematopoietic stem cell transplantation (allo-HSCT) could be a valuable treatment choice for TP53+ myeloid tumors, such as acute myeloid leukemia and myelodysplastic syndrome.
- Conditions
- TP53, Myeloid Tumors, Conditioning, Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- NCT04123392
- Testing
- Decitabine, Busulfan (BU), Cyclophosphamide (CY)
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Adult Solid Neoplasm, Bladder Carcinoma
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
This phase I trial studies the side effects of vaccine therapy and pembrolizumab in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment, that…
- Conditions
- Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative
- Trial name
- NCT02432963
- Testing
- Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- City of Hope Medical Center
CNS Malignancies, Medulloblastoma Recurrent
A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.
This clinical trial is studying a drug called SGT-53 along with radiation and another drug called Nivolumab. It's for children with brain tumors that have come back, gotten worse, or didn't get better with earlier treatments.
- Conditions
- CNS Malignancies, Medulloblastoma Recurrent, ATRT Recurrent, Pineoblastoma
- Trial name
- JACOB (NCT07017816)
- Testing
- SGT-53, hypofractionated radiotherapy with immunotherapy, Nivolumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Children's National Research Institute
Li-Fraumeni Syndrome
A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome
Background: Li Fraumeni Syndrome (LFS) is a highly penetrant, autosomal dominant cancer predisposition disorder. Four main cancer types including sarcoma, adrenocortical carcinoma, breast cancer, and malignant brain tumors…
- Trial name
- NCT01981525
- Testing
- Metformin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer
A prospective, multi-center, phase II study of 21 patients to evaluate the efficacy of the epidermal growth factor receptor (EGFR) inhibitor, Cetuximab in patients with metastatic colorectal cancer (mCRC) harboring Adenomatous…
- Trial name
- APK Mutant (NCT04853043)
- Testing
- Cetuximab
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Utah
Endometrial Cancer
Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation
Aim to compare chemotherapy alone or chemoradiotherapy for post-operative endometrial cancer (stage I-IVA) with p53 mutation.
- Trial name
- NCT05489848
- Testing
- Paclitaxel, Carboplatin, Cisplatin
- Volunteers
- 294 people
- Sponsor
- Fudan University
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission, Hematopoietic Cell Transplantation Recipient, JAK2 Gene Mutation
- Trial name
- NCT03272633
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Irradiated Allogeneic Cells
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Rutgers, The State University of New Jersey